
    
      This is a prospective, multi-center, single-arm superiority trial to assess the TAXUS®
      Element™ Paclitaxel-Eluting Coronary Stent System for the treatment of de novo
      atherosclerotic lesions of ≤20 mm in length in native coronary arteries with visual RVD of ≥
      2.25 mm to < 2.75 mm diameter.

      Two hundred twenty-four (224) subjects will be treated with the TAXUS Element stent at a
      maximum of 35 clinical sites. Follow-up at 30 days, 9 months including angiography) and 1
      year will be completed in all subjects enrolled in the study. Eligible subjects will have
      annual follow-up until 5 years post-index procedure.
    
  